<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03972696</url>
  </required_header>
  <id_info>
    <org_study_id>GIC-RAD-2016-01</org_study_id>
    <nct_id>NCT03972696</nct_id>
  </id_info>
  <brief_title>OPTimizing Irradiation Through Molecular Assesment of Lymph Node After Primary Systemic Treatment</brief_title>
  <acronym>OPTIMALIIa</acronym>
  <official_title>OPTimizing Irradiation Through Molecular Assesment of Lymph Node After Primary Systemic Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo de Investigación Clínica en Oncología Radioterapia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo de Investigación Clínica en Oncología Radioterapia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breast cancer management integrating surgery, systemic therapy and radiation therapy tends to
      systemic treatment as the first therapeutic option, continuing afterwards by surgery and
      radiation therapy with the scope of decreasing the locoregional treatment. This strategy
      implies doubts about what should be the locoregional treatment, because many patients have
      remissions and a significant number of them a complete response. The responses are associated
      with better clinical outcome although there are doubts about they are a surrogate marker of
      survival.

      Nodal irradiation after systemic treatment in patients with breast cancer it is under
      discussion, particularly in the case of patients with initial clinical involvement
      experiencing complete remission. For this reason, some groups decide irradiation of all nodal
      regions and others choose no irradiation of the lymph nodes at all. To clarify this
      discussion the present study is proposed.

      The &quot;One Step Nucleic Amplification&quot; (OSNA) is a technique developed by Sysmex Corporation
      that allows a complete analysis of sentinel nodes and provides a quantification of the tumor
      marker Cytokeratin 19 (CK19) messenger ribonucleic acid (mRNA) in the sentinel node. The
      result is expressed by the Tumour Load as number of copies per microliter. This technique has
      shown its diagnostic ability both without primary systemic treatment and after primary
      systemic treatment, being more reproducible than conventional processes.

      In spite of this, fits to mention that the studies of validation used to obtain the European
      Conformity (CE) mark only included patients without previous systemic treatment to the
      surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast cancer management integrating surgery, systemic therapy and radiation therapy tends to
      systemic treatment as the first therapeutic option, continuing afterwards by surgery and
      radiation therapy with the scope of decreasing the locoregional treatment. This strategy
      implies doubts about what should be the locoregional treatment, because many patients have
      remissions and a significant number of them a complete response. The responses are associated
      with better clinical outcome although there are doubts about they are a surrogate marker of
      survival.

      According to a previous publication, in which the predictors of locoregional recurrence
      National Surgical Adjuvant Breast and Bowel Project 18 (NSABP18) and National Surgical
      Adjuvant Breast and Bowel Project 27 (NSABP27) studies are evaluated, both studies designed
      for viewing the value of neoadjuvant chemotherapy, good results of locoregional control are
      described, although in many cases radiotherapy was omitted or lymph node were not irradiated.

      Therefore the need to nodal irradiation begins to be questioned, especially when they are
      negative after primary systemic treatment, regardless of their previous state. However the
      clinical guidelines recommend radiotherapy planning according to the previous stage. The
      problem is the local treatment indication is established based on the indications of
      irradiation without primary systemic therapy, as showed in retrospective studies, without the
      existence of randomized studies designed to analyze the role of radiotherapy in these
      circumstances. In the last American Society of Clinical Oncology (ASCO) preliminary results
      of a meta-analysis including three large studies of primary systemic treatment were
      presented.

      Results show that irradiation improves local control in N1 patients achieving a complete
      remission, radiotherapy being an independent prognostic factor, in terms of locoregional
      control; however, they conclude that the optimal selection of patients remains unclear. The
      controversy remains, because there is no evidence to treat nodes after primary systemic
      therapy, whether there is a complete remission as if it does not, nor is it known that
      subgroup of patients may benefit more from local treatments. Long-term studies are needed to
      analyze this issue, leaving the decision being especially complicated in cases of clinically
      positive nodes experiencing a complete remission. The problem remains that often is not known
      exactly has been irradiated since, in many studies, irradiation is indicated at the
      discretion of the researcher.

      Given these doubts, European Society conducted a survey to find out what was the attitude
      about these patients, and the findings shows that 75% of the centers irradiate in the N1
      case. The American Society obtained similar results and in Spain 64% of respondents irradiate
      the lymph nodes. These three publications conclude that studies are needed to determine the
      importance of irradiation after primary systemic treatment and while waiting for these
      results, a consensus muts be reached as stated in ASCO 2015 summary.

      The &quot;One Step Nucleic Amplification&quot; (OSNA) is a technique developed by Sysmex Corporation
      that allows a complete analysis of sentinel nodes and provides a quantification of the tumor
      marker CK19 mRNA in the sentinel node. The result is expressed by the Tumour Load as number
      of copies per microliter. This technique has shown its diagnostic ability both without
      primary systemic treatment and after primary systemic treatment, being more reproducible than
      conventional processes.

      In spite of this, fits to mention that the studies of validation used to obtain the CE mark
      only included patients without previous systemic treatment to the surgery.

      In summary, nodal irradiation after systemic treatment in patients with breast cancer it is
      under discussion, particularly in the case of patients with initial clinical involvement
      experiencing complete remission. For this reason, some groups decide irradiation of all nodal
      regions and others choose no irradiation of the lymph nodes at all. To clarify this
      discussion the present study is proposed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To show the non-inferiority of (BA2) compared to (BA3S), in terms of 5-years diseasefree survival (DFS), including the local, regional and distant disease free survival and excluding second neoplasms</measure>
    <time_frame>5 years</time_frame>
    <description>The primary outcome will be the 5-years DFS. DFS is defined as the time from randomization to any breast cancer-related event, including local, regional or distant recurrence, or death from breast cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the 5-years incidence of loco-regional tumor recurrence between BA2 and BA3S.</measure>
    <time_frame>5 Years</time_frame>
    <description>Loco-regional recurrence during the 5-years follow-up, defined as clinical or image-based detection of tumour in treated breast or thoracic wall (local recurrence) or in the ipsilateral axilla or supraclavicular fossa or internal mammary chain (regional recurrence).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the 5-years incidence of distant tumor recurrence between BA2 and BA3S</measure>
    <time_frame>5 years</time_frame>
    <description>Distant recurrence rate occurring during the 5-years follow-up, defined as clinical or image-based detection of neoplastic affectation of other organs or tissues different from the treated breast, ipsilateral axilla or supraclavicular fossa or internal mammary chain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the acute and chronic toxicity of the two treatment modalities.</measure>
    <time_frame>5 years</time_frame>
    <description>Toxicity, recorded using the Terminology Criteria for Adverse Events v4.0 (CTCAE).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1212</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>BA3S</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiotherapy (RT) will be administered, in the breast or thoracic wall, axillary levels I, II and III, and supraclavicular node areas, with optimization of the technique Intentional irradiation of lymph nodes: Patients will receive a total dose of 50 Gy in the whole breast and nodal areas (axillary I, II, III, and supraclavicular) with optimization of the technique, in daily fractions of 2 Gy and 5 fractions/week during 5 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BA2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RT will be administered, in the breast or thoracic wall and axillary levels I and II, with optimization of the technique Incidental irradiation of lymph nodes: Patients will receive a total dose of 50 Gy in the whole breast, but not aimed at nodal areas, with optimization of the technique, in daily fractions of 2 Gy and 5 fractions/week during 5 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Irradiation</intervention_name>
    <description>BA3S versus BA2 irradiation of lymphatic node areas, administered using a lineal accelerator, after 3D delimitation of the supraclavicular and axillary levels I, II and III. In both treatment arms, further tumoral bed boost will be allowed according to the investigator criteria, whether dose contribution to the nodal areas can be calculated. Due to its nature, interventions cannot be asked.</description>
    <arm_group_label>BA2</arm_group_label>
    <arm_group_label>BA3S</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infiltrating carcinoma of the breast.

          -  Metastatic lymph nodes (N1) at diagnosis, as determined histologically by Fine Needle
             Aspiration or Core Needle Biopsy.

          -  Primary systemic therapy (including antiestrogen or chemotherapy, and targeted
             therapies).

          -  Tumour surgery: tumorectomy, quadrantectomy or mastectomy.

          -  OSNA (ND) or - lymph nodes after primary systemic therapy.

          -  Age ≥ 18 years old.

          -  Karnofsky Index ≥ 70 %.

          -  Signed Informed Consent.

        Exclusion Criteria:

          -  Lymphadenectomy.

          -  Bilateral breast cancer.

          -  Males.

          -  Previous thoracic irradiation therapy.

          -  Contraindications of radiotherapy (pregnancy, severe collagen diseases).

          -  Other neoplasms.

          -  Severe associated comorbidities that, according to the investigator criteria, may
             interfere with the study evaluations.

          -  Lymp nodes OSNA -(L), +, ++ after primary systemic therapy.

          -  Sentinel lymph node biopsy previous to the primary systemic therapy.

          -  Mammary internal chain affected.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel Algara Lopez, Medicine</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grupo de Investigación Clínica en Oncología Radioterápica (GICOR)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manuel Algara Lopez, Medicine</last_name>
    <phone>+34933674144</phone>
    <email>MAlgara@parcdesalutmar.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario de Cruces</name>
      <address>
        <city>Barakaldo</city>
        <state>Bilbao</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andere Frías, Medicine</last_name>
      <email>anderefrias@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Araba</name>
      <address>
        <city>Vitoria</city>
        <state>Pais Vasco</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Flaquer, Medicine</last_name>
      <email>amandafg@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Sant Joan de Reus</name>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meritxell Arenas, Medicine</last_name>
      <email>marenas@grupsagessa.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Oncológico de Galicia</name>
      <address>
        <city>A Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inma Díaz, Medicine</last_name>
      <email>inma.diaz@cog.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Cristina</name>
      <address>
        <city>Badajoz</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yesika Rios, Medicine</last_name>
      <email>yesikarios@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO Badalona</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Mª Ballester</last_name>
      <email>rballester@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Santa Lucía</name>
      <address>
        <city>Cartagena</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Salinas, Medicine</last_name>
      <email>juan.salinas@carm.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Donostia</name>
      <address>
        <city>Donostia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Guimón, Medicine</last_name>
      <email>elena.guimonolaizola@osakidetza.eus</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO Girona</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arantxa Eraso, Medicine</last_name>
      <email>aeraso@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova</name>
      <address>
        <city>Lerida</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginia García, Medicine</last_name>
      <email>vgarciareglero@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anxela Doval, Medicine</last_name>
      <email>anxeladoval@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Celedonio Varas, Medicine</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregrorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Calin, Medicine</last_name>
      <email>ana.calin.lorca@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurea Manso de Lema, Medicine</last_name>
      <email>aureamanso@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mercedes Martín, Medicine</last_name>
      <email>merchibouh@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Antonio Lozano Martínez, Medicine</last_name>
      <email>antoniojlozano@live.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel García, Medicine</last_name>
      <email>isabel.garciarios@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Carrasco, Medicine</last_name>
      <email>francisco_cp84@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Luís López Guerra, Medicine</last_name>
      <email>chanodetriana@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amparo González, Medicine</last_name>
      <email>agonzalez@eresa.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014 Jul 12;384(9938):164-72. doi: 10.1016/S0140-6736(13)62422-8. Epub 2014 Feb 14. Review. Erratum in: Lancet. 2019 Mar 9;393(10175):986.</citation>
    <PMID>24529560</PMID>
  </reference>
  <reference>
    <citation>Mamounas EP, Anderson SJ, Dignam JJ, Bear HD, Julian TB, Geyer CE Jr, Taghian A, Wickerham DL, Wolmark N. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol. 2012 Nov 10;30(32):3960-6. doi: 10.1200/JCO.2011.40.8369. Epub 2012 Oct 1.</citation>
    <PMID>23032615</PMID>
  </reference>
  <reference>
    <citation>Noh JM, Park W, Suh CO, Keum KC, Kim YB, Shin KH, Kim K, Chie EK, Ha SW, Kim SS, Ahn SD, Shin HS, Kim JH, Lee HS, Lee NK, Huh SJ, Choi DH. Is elective nodal irradiation beneficial in patients with pathologically negative lymph nodes after neoadjuvant chemotherapy and breast-conserving surgery for clinical stage II-III breast cancer? A multicentre retrospective study (KROG 12-05). Br J Cancer. 2014 Mar 18;110(6):1420-6. doi: 10.1038/bjc.2014.26. Epub 2014 Jan 30.</citation>
    <PMID>24481403</PMID>
  </reference>
  <reference>
    <citation>Shim SJ, Park W, Huh SJ, Choi DH, Shin KH, Lee NK, Suh CO, Keum KC, Kim YB, Ahn SD, Kim SS, Ha SW, Chie EK, Kim K, Shin HS, Kim JH, Lee HS. The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage II-III breast cancer patients with pN0: a multicenter, retrospective study (KROG 12-05). Int J Radiat Oncol Biol Phys. 2014 Jan 1;88(1):65-72. doi: 10.1016/j.ijrobp.2013.09.021. Epub 2013 Oct 22.</citation>
    <PMID>24161425</PMID>
  </reference>
  <reference>
    <citation>Nagar H, Boothe D, Ginter PS, Sison C, Vahdat L, Shin S, Smith M, Chao KS, Nori D, Hayes MK. Disease-free survival according to the use of postmastectomy radiation therapy after neoadjuvant chemotherapy. Clin Breast Cancer. 2015 Apr;15(2):128-34. doi: 10.1016/j.clbc.2014.09.012. Epub 2014 Nov 11.</citation>
    <PMID>25459070</PMID>
  </reference>
  <reference>
    <citation>Bernier J. Post-mastectomy radiotherapy after neodjuvant chemotherapy in breast cancer patients: A review. Crit Rev Oncol Hematol. 2015 Mar;93(3):180-9. doi: 10.1016/j.critrevonc.2014.10.011. Epub 2014 Oct 31. Review.</citation>
    <PMID>25465740</PMID>
  </reference>
  <reference>
    <citation>White J, Mamounas E. Locoregional radiotherapy in patients with breast cancer responding to neoadjuvant chemotherapy: a paradigm for treatment individualization. J Clin Oncol. 2014 Feb 20;32(6):494-5. doi: 10.1200/JCO.2013.53.4974. Epub 2013 Dec 30.</citation>
    <PMID>24378411</PMID>
  </reference>
  <reference>
    <citation>Marks LB, Prosnitz LR. Reducing local therapy in patients responding to preoperative systemic therapy: are we outsmarting ourselves? J Clin Oncol. 2014 Feb 20;32(6):491-3. doi: 10.1200/JCO.2013.51.3523. Epub 2013 Dec 30.</citation>
    <PMID>24378409</PMID>
  </reference>
  <reference>
    <citation>Smith BD. Using chemotherapy response to personalize choices regarding locoregional therapy: a new era in breast cancer treatment? J Clin Oncol. 2012 Nov 10;30(32):3913-5. doi: 10.1200/JCO.2012.44.4539. Epub 2012 Oct 1.</citation>
    <PMID>23032624</PMID>
  </reference>
  <reference>
    <citation>Mamounas EP. Impact of neoadjuvant chemotherapy on locoregional surgical treatment of breast cancer. Ann Surg Oncol. 2015 May;22(5):1425-33. doi: 10.1245/s10434-015-4406-6. Epub 2015 Mar 2. Review.</citation>
    <PMID>25727558</PMID>
  </reference>
  <reference>
    <citation>Rusthoven CG, Rabinovitch RA, Jones BL, Koshy M, Amini A, Yeh N, Jackson MW, Fisher CM. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis. Ann Oncol. 2016 May;27(5):818-27. doi: 10.1093/annonc/mdw046. Epub 2016 Feb 9.</citation>
    <PMID>26861597</PMID>
  </reference>
  <reference>
    <citation>Belkacemi Y, Kaidar-Person O, Poortmans P, Ozsahin M, Valli MC, Russell N, Kunkler I, Hermans J, Kuten A, van Tienhoven G, Westenberg H; Breast Working Party of the EORTC Radiation Oncology Group (ROG). Patterns of practice of regional nodal irradiation in breast cancer: results of the European Organization for Research and Treatment of Cancer (EORTC) NOdal Radiotherapy (NORA) survey. Ann Oncol. 2015 Mar;26(3):529-35. doi: 10.1093/annonc/mdu561. Epub 2014 Dec 5.</citation>
    <PMID>25480875</PMID>
  </reference>
  <reference>
    <citation>Haffty BG, McCall LM, Ballman KV, McLaughlin S, Jagsi R, Ollila DW, Hunt KK, Buchholz TA, Boughey JC. Patterns of Local-Regional Management Following Neoadjuvant Chemotherapy in Breast Cancer: Results From ACOSOG Z1071 (Alliance). Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):493-502. doi: 10.1016/j.ijrobp.2015.11.005. Epub 2015 Nov 10.</citation>
    <PMID>26867878</PMID>
  </reference>
  <reference>
    <citation>Arenas M, Montero Á, de Las Peñas MD, Algara M. The position and current status of radiation therapy after primary systemic therapy in breast cancer: a national survey-based expert consensus statement. Clin Transl Oncol. 2016 Jun;18(6):582-91. doi: 10.1007/s12094-015-1401-0. Epub 2015 Sep 14.</citation>
    <PMID>26370420</PMID>
  </reference>
  <reference>
    <citation>Dizon DS, Krilov L, Cohen E, Gangadhar T, Ganz PA, Hensing TA, Hunger S, Krishnamurthi SS, Lassman AB, Markham MJ, Mayer E, Neuss M, Pal SK, Richardson LC, Schilsky R, Schwartz GK, Spriggs DR, Villalona-Calero MA, Villani G, Masters G. Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2016 Mar 20;34(9):987-1011. doi: 10.1200/JCO.2015.65.8427. Epub 2016 Feb 4.</citation>
    <PMID>26846975</PMID>
  </reference>
  <reference>
    <citation>Tsujimoto M, Nakabayashi K, Yoshidome K, Kaneko T, Iwase T, Akiyama F, Kato Y, Tsuda H, Ueda S, Sato K, Tamaki Y, Noguchi S, Kataoka TR, Nakajima H, Komoike Y, Inaji H, Tsugawa K, Suzuki K, Nakamura S, Daitoh M, Otomo Y, Matsuura N. One-step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients. Clin Cancer Res. 2007 Aug 15;13(16):4807-16.</citation>
    <PMID>17699859</PMID>
  </reference>
  <reference>
    <citation>Di Filippo F, Giannarelli D, Bouteille C, Bernet L, Cano R, Cunnick G, Sapino A. Elaboration of a nomogram to predict non sentinel node status in breast cancer patients with positive sentinel node, intra-operatively assessed with one step nucleic acid amplification method. J Exp Clin Cancer Res. 2015 Nov 4;34:136. doi: 10.1186/s13046-015-0246-2.</citation>
    <PMID>26538019</PMID>
  </reference>
  <reference>
    <citation>Navarro-Cecilia J, Dueñas-Rodríguez B, Luque-López C, Ramírez-Expósito MJ, Martínez-Ferrol J, Ruíz-Mateas A, Ureña C, Carrera-González MP, Mayas MD, Martínez-Martos JM. Intraoperative sentinel node biopsy by one-step nucleic acid amplification (OSNA) avoids axillary lymphadenectomy in women with breast cancer treated with neoadjuvant chemotherapy. Eur J Surg Oncol. 2013 Aug;39(8):873-9. doi: 10.1016/j.ejso.2013.05.002. Epub 2013 May 25.</citation>
    <PMID>23711734</PMID>
  </reference>
  <reference>
    <citation>Tamaki Y. One-step nucleic acid amplification assay (OSNA) for sentinel lymph node biopsy. Breast Cancer. 2015 May;22(3):230-4. doi: 10.1007/s12282-012-0390-x. Epub 2012 Aug 9. Review.</citation>
    <PMID>22875641</PMID>
  </reference>
  <reference>
    <citation>Offersen BV, Boersma LJ, Kirkove C, Hol S, Aznar MC, Biete Sola A, Kirova YM, Pignol JP, Remouchamps V, Verhoeven K, Weltens C, Arenas M, Gabrys D, Kopek N, Krause M, Lundstedt D, Marinko T, Montero A, Yarnold J, Poortmans P. ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. Radiother Oncol. 2015 Jan;114(1):3-10. doi: 10.1016/j.radonc.2014.11.030. Epub 2015 Jan 24.</citation>
    <PMID>25630428</PMID>
  </reference>
  <reference>
    <citation>von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012 May 20;30(15):1796-804. doi: 10.1200/JCO.2011.38.8595. Epub 2012 Apr 16.</citation>
    <PMID>22508812</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>May 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2019</study_first_posted>
  <last_update_submitted>July 31, 2019</last_update_submitted>
  <last_update_submitted_qc>July 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

